CFDE Data Portal | Search ZNF350-AS1

	Label	Description
	ZNF350-AS1 associations Collection (Entity type)	Associations for ZNF350-AS1_associations
	ZNF350-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	ZNF350-AS1 Gene (Entity type)	ENSG00000269235 - ZNF350 antisense RNA 1
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 4 V 1 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125014 enzalutamide prostate gland 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE137325 2 V 0 COPANLISIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE171177,GSE171181 1 V 0 E7107 HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE135352 6 V 4 NAPABUCASIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

ZNF350-AS1 associations

Associations for ZNF350-AS1_associations

ZNF350-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

ZNF350-AS1

ENSG00000269235 - ZNF350 antisense RNA 1

GSE195663 cisplatin 7 v 1 human dn

A Gene Set from LINCS

GSE120612 4 V 1 ETOPOSIDE HUMAN UP

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 6 human up

A Gene Set from LINCS

GSE125014 enzalutamide prostate gland 1 v 5 human up

A Gene Set from LINCS

GSE137325 2 V 0 COPANLISIB HUMAN UP

A Gene Set from LINCS

GSE171177,GSE171181 1 V 0 E7107 HUMAN UP

A Gene Set from LINCS

GSE135352 6 V 4 NAPABUCASIN HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.